NCT07195916 · Incyte Corporation
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
What this study is about
A study to evaluate the safety and how well patients handle the treatment of INCA036873 in participants with advanced solid tumors and hematological malignancies.
View original scientific description
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age ≥18 years.
- ECOG performance status of 0 or 1.
- Histologically confirmed:
- Clear cell renal cell carcinoma (ccRCC).
- Diffuse large B-cell lymphoma (DLBCL, NOS).
- High-grade B-cell lymphoma (HGBCL).
- Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
- Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
- Disease progression, relapse, or refractory to prior therapy:
- ccRCC: ≥1 prior line incl. ICI + TKI.
- DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
- PTCL/CTCL: ≥1 prior systemic therapy.
- Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
- Tumor tissue available for central testing.
Exclusion criteria
- Untreated or progressive CNS disease unless previously treated and stable.
- Other active invasive malignancy within 2 years (except certain low-risk cancers).
- Prior CD70-targeting therapy, including CAR T.
- ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
- Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
- Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
- Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
- Pregnancy, breastfeeding, or unwillingness to use effective contraception. Other protocol-defined Inclusion/Exclusion Criteria may apply.
Where
- Duarte, California
- La Jolla, California
- Ann Arbor, Michigan
- Omaha, Nebraska
- New York, New York
- Nashville, Tennessee
- Houston, Texas
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 30, 2026 · Source of record for eligibility and locations